ARCHIVES

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 32 No. 12 | December 25, 2009

Download PDF Visit The Full Archive

Related Articles

ORI Says COMS Study Coordinator Committed Scientific Misconduct

April 12, 1996

Dana-Farber Correction Plan Sent To State; Pharmacy Chief Resigns

June 9, 1995

Obama Executive Order Gives FDA Authority To Combat Drug Shortages

November 4, 2011

Chabner Says Vials DCT Obtained From Burton Operation Were Contaminated

June 8, 1984

ASCO Briefing Highlights Seven Studies That Could Change Clinical Practice

May 29, 2009

Control AC Hear Report On High Risk conference, Messer Survey

September 6, 1974